This symposium took place on 22th May 2016 as part of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress 2016 in Vienna, Austria
Chairperson: Markus Ketteler1
Co-chairperson: Alexander Rosenkranz2
Speakers: Laurent Juillard,3 Philip Kalra4
1. Department of Nephrology, Klinikum Coburg, Coburg, Germany
2. Division of Nephrology, Medical University of Graz, Graz, Austria
3. Nephrology Department, Hospital Edouard Herriot, Lyon, France
4. Department of Renal Medicine, Salford Royal Hospital, Manchester, UK
Disclosure: Prof Ketteler has served as a consultant for Pfizer, Amgen, Vifor Fresenius Medical Care Renal Pharma, Abbvie, and Sanifit; has received honoraria for lectures on behalf of Amgen, Vifor Fresenius Medical Care Renal Pharma, Sanofi, Shire, Pfizer, and Amgen; and served as a Principle Investigator for Medice. Prof Rosenkrantz has received honoraria for lectures on behalf of Amgen, Mitsubishi, Novartis, Boehringer, Astropharma, Baxter, Fresenius, Takeda, and Abbott/Abbvie. Prof Juillard has received honoraria for lectures from B. Braun, Genzyme, GE Heathcare, and Vifor Fresenius Medical Care Renal Pharma; he has also sat on advisory boards for Baxter, Fresenius Pharma, GE Healthcare, Hemotech, Roche, and Vifor Pharma; and received clinical research/research support from Alexion, Bayer, GlaxoSmithKline, Otsuka, Baxter, Fresenius Pharma, and Genzyme. Prof Kalra has received honoraria for lectures on behalf of Vifor Fresenius Medical Care Renal Pharma, Sanofi, Shire, and received an educational grant from Shire supporting biomarker research. Prof Kalra has also contributed to the design of the VERIFIE:PASS study, sponsored by Vifor Fresenius Medical Care Renal Pharma.
Acknowledgements: Writing assistance was provided by Kabira Alieva, ApotheCom.
Support: The symposium was sponsored by Vifor Fresenius Medical Care Renal Pharma. Authors received honoraria for preparation and delivery of their presentations. The views and opinions expressed are those of the authors and not necessarily of Vifor Fresenius Medical Care Renal Pharma.
Citation: EMJ Nephrol. 2016;4:28–35.
Prof Alexander Rosenkranz and Prof Markus Ketteler welcomed the audience and the expert panel of the symposium, and briefly described the programme of the meeting. Prof Laurent Juillard discussed the challenges faced in achieving phosphate control in patients on haemodialysis, as well as aspects for optimising the management of hyperphosphataemia. Prof Philip Kalra described recent advances in hyperphosphataemia treatment, concentrating on an iron-based, calcium-free phosphate binder that may offer a lower pill burden compared with previous treatments, and thereby address the challenge of patient non-adherence.